

## REFERENCES

1. Metchock BG, Nolte FS, Wallace RJ. *Mycobacterium*. In: Murray PR., Baron EJ., Tenover FC., Tenover FC., Tenover FC., et al. Manual of clinical microbiology. 7 th ed. Washington DC: ASM Press;1999;399-437.
2. Troesch A, Nguyen H, Miyada CG, et al. *Mycobacterium* species identification and rifampin resistance testing with high-density DNA probe arrays. *J Clin Microbiol*. 1999;37(1):49-55.
3. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. *Bull WHO*72: 1994: 213-220.
4. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global surveillance and Monitoring Project. *JAMA*: 1999: 677-86.
5. Park H, Jang H, Kim C, et al. Detection and identification of mycobacteria by amplification of the internal transcribed spacer regions with genus- and species-specific PCR primers. *J Clin Microbiol*. 2000;38(11):4080-5.
6. [http://www.who.int/tb/publications/global\\_report/2006/pdf/full\\_report\\_correctedversion.pdf](http://www.who.int/tb/publications/global_report/2006/pdf/full_report_correctedversion.pdf)
7. [http://data.unaids.org/pub/Report/2008/who2008globaltbreport\\_en.pdf](http://data.unaids.org/pub/Report/2008/who2008globaltbreport_en.pdf)
8. Lachnik J, Ackermann B, Bohrsen A, et al. Rapid-cycle PCR and fluorimetry for detection of mycobacteria. *J Clin Microbiol*. 2002;40(9):3364-73.
9. Miller N, Infante S, Cleary T. Evaluation of the LiPA MYCOBACTERIA assay for identification of mycobacterial species from BACTEC 12B bottles. *J Clin Microbiol*. 2000;38(5):1915-9.
10. Kox LF, van Leeuwen J, Knijper S, et al. PCR assay based on DNA coding for 16S rRNA for detection and identification of mycobacteria in clinical samples. *J Clin Microbiol*. 1995;33(12):3225-33.
11. Wagner D, Young LS. Nontuberculous mycobacterial infections: a clinical review. *Infection*. 2004;32(5):257-70.

12. Ahn CH, Lowell JR, Onstad GD, Shuford EH, Hurst GA. A demographic study of disease due to *Mycobacterium kansasii* or *M. intracellulare-avium* in Texas. *Chest*. 1979; 75: 120-5.
13. Wolinsky E. State of the art: non-tuberculous mycobacteria and associated disease. *Am Rev Respir Dis*. 1979; 119: 107-59.
14. De Beenhouwer H, Liang Z, De Rijk P, *et al*. Detection and identification of mycobacteria by DNA amplification and oligonucleotide-specific capture plate hybridization. *J Clin Microbiol*. 1995;33(11):2994-8.
15. Nightingale SD, Byrd LT, Southern PM, *et al*. Incidence of *Mycobacterium avium-intracellulare* complex bacteremia in human immunodeficiency virus-positive patients. *J Infect Dis*. 1992;165(6):1082-5.
16. Horsburgh CR, Jr. *Mycobacterium avium* complex infection in the acquired immunodeficiency syndrome. *N Engl J Med*. 1991;324(19):1332-8.
17. Prince DS, Peterson DD, Steiner RM, *et al*. Infection with *Mycobacterium avium* complex in patients without predisposing conditions. *N Engl J Med*. 1989;321(13):863-8.
18. Nuchprayoon C, Thanabodi P, Chinachoti N. Pulmonary disease due to photochromogenic mycobacterial infection. *J Med Assoc Thai*. 1968; 51: 923-32.
19. Chetchotisakd P, Mootsikapun P, Anunnatsiri S, *et al*. Disseminated infection due to rapidly growing mycobacteria in immunocompetent hosts presenting with chronic lymphadenopathy: a previously unrecognized clinical entity. *Clin Infect Dis*. 2000;30(1):29-34.
20. Shafer RW, Sierra MF. *Mycobacterium xenopi*, *Mycobacterium fortuitum*, *Mycobacterium kansasii*, and other nontuberculous mycobacteria in an area of endemicity for AIDS. *Clin Infect Dis*. 1992;15(1):161-2.
21. Holland SM. Nontuberculous mycobacteria. *Am J Med Sci*. 2001;321(1):49-55.
22. Saritsiri S, Udomsantisook N, Suankraatay S. Nontuberculous Mycobacterail in fections in King Chulalongkorn Memorial Hospital. *J med Assoc Thai*. 2006;89(12): 2035-45.
23. Kunyanone N. DNA fingerprinting of *Mycobacterium avium* in HIV-infected patients. Division of Clinical Microbiology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiangmai University. 2004.

24. Fletcher HA, Donoghue HD, Holton J, *et al.* Widespread occurrence of *Mycobacterium tuberculosis* DNA from 18th-19th century Hungarians. *Am J Phys Anthropol.* 2003;120(2):144-52.
25. Sanguinetti M, Posteraro B, Ardito F, *et al.* Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of *Mycobacterium* species growing in liquid media. *J Clin Microbiol.* 1998;36(6):1530-3.
26. Butler WR, Jost KC, Jr., Kilburn JO. Identification of mycobacteria by high-performance liquid chromatography. *J Clin Microbiol.* 1991;29(11):2468-72.
27. Xiong L, Kong F, Yang Y, *et al.* Use of PCR and reverse line blot hybridization macroarray based on 16S-23S rRNA gene internal transcribed spacer sequences for rapid identification of 34 mycobacterium species. *J Clin Microbiol.* 2006;44(10):3544-50.
28. Roth A, Fischer M, Hamid ME, *et al.* Differentiation of phylogenetically related slowly growing mycobacteria based on 16S-23S rRNA gene internal transcribed spacer sequences. *J Clin Microbiol.* 1998;36(1):139-47.
29. Lappayawichit P, Rienthong S, Rienthong D, *et al.* Differentiation of *Mycobacterium* species by restriction enzyme analysis of amplified 16S-23S ribosomal DNA spacer sequences. *Tuber Lung Dis.* 1996;77(3):257-63.
30. Lebrun L, Espinasse F, Poveda JD, *et al.* Evaluation of nonradioactive DNA probes for identification of mycobacteria. *J Clin Microbiol.* 1992;30(9):2476-8.
31. Wayne, L.G. and Kubica, 1986. The mycobacteria. In; Sneath, P.H.A., Mair, N.S., *et al.* (eds), *Bergey's manual of systemic bacteriology*, 8<sup>th</sup> edn. Baltimor, MD; Williams & Wilkins, 1436 – 57.
32. Anuchapreeda S, Tima S, Duangrat C, *et al.* Effect of pure curcumin, demethoxycurcumin, and bisdemethoxycurcumin on WT1 gene expression in leukemic cell lines. *Cancer Chemother Pharmacol.* 2008;62(4):585-94.
33. Hansen, G.A. 1880. *Bacillus leprae*. *Virchows Archiv.*79, 32 -34.
34. Koch, R. 1882. Die Aetiologie der Tuberkulose. *Berl Klin Wochnerscher*,19, 221-30.
35. Lehmann, K.B., and Neumann, 1896. *Atlas and Grandriss der Bakteriologie und Lehrbuch der speciellen bakteriologischen Diagnostik*. Munich: JF Lehmann.

36. Kazda, J.F. 1983. The principles of the ecology of mycobacteria. In: Ratledge, C. and Stanford, J.(eds). *The biology of the Mycobacteria*, Vol.2., London: Academic Press. 323-415.
37. Weiss TC, Romaniuk PJ. Contribution of individual amino acids to the RNA binding activity of the Wilms' tumor suppressor protein WT1. *Biochemistry*. 2009;48(1):148-55.
38. Hartmans, S. and De Bont, J.A.M. 1992. The genus *Mycobacterium* nonmedical. In: Ballows, A., Truper, H.G. et.al. (eds), *The prokaryotes: a handbook on the biology of bacteria: ecophysiology, isolation, identification, applications*, 2<sup>nd</sup> edn. New York: springer Verlag, 1214 -37.
39. Wheeler. P.R. and Ratledge. C. 1994. Metabolism of *Mycobacterium tuberculosis*. In: bloom. B.R. (ed). *Tuberculosis, pathogenesis, protection, and control*. Washington. DC: American society for microbiology Press. 353-85.
40. Kearns GL, Wheeler JG, Childress SH, et al. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. *J Pediatr*. 1994;125(5 Pt 1):805-11.
41. Gobin J, Moore CH, Reeve JR, Jr., et al. Iron acquisition by *Mycobacterium tuberculosis*: isolation and characterization of a family of iron-binding exochelins. *Proc Natl Acad Sci U S A*. 1995;92(11):5189-93.
42. McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, et al. Persistence of *Mycobacterium tuberculosis* in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. *Nature*. 2000;406(6797):735-8.
43. Bersa. G.S. and Chatterjee. D. 1994. Lipids and carbohydrates of *Mycobacterium tuberculosis*. In: bloom. B.R. (ed). *Tuberculosis, pathogenesis, protection, and control*. Washington. DC: American society for microbiology Press. 285-306.
44. Brennan. P.J. and Drapper. P. 1994. Ultrastructure of *Mycobacterium tuberculosis*. In: bloom. B.R. (ed). *Tuberculosis, pathogenesis, protection, and control*. Washington. DC: American society for microbiology Press. 271-84.
45. Stewart-Tull, D.E.S. 1983. Immunologically important constituents of mycobacteria: adjuvants. In: Ratledge, C. and Stanford, J.L. (eds), *The biology of the Mycobacteria*, Vol. 2. London: Acadmic Press, 3-84.

46. Battey J, Moulding C, Taub R, *et al.* The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. *Cell*. 1983;34(3):779-87.
47. Chatterjee D, Hunter SW, McNeil M, *et al.* Lipoarabinomannan. Multiglycosylated form of the mycobacterial mannosylphosphatidylinositols. *J Biol Chem*. 1992;267(9):6228-33.
48. Chatterjee D, Lowell K, Rivoire B, *et al.* Lipoarabinomannan of *Mycobacterium tuberculosis*. Capping with mannosyl residues in some strains. *J Biol Chem*. 1992;267(9):6234-9.
49. Chatterjee D, Roberts AD, Lowell K, *et al.* Structural basis of capacity of lipoarabinomannan to induce secretion of tumor necrosis factor. *Infect Immun*. 1992;60(3):1249-53.
50. Kaplan G, Gandhi RR, Weinstein DE, *et al.* *Mycobacterium leprae* antigen-induced suppression of T cell proliferation in vitro. *J Immunol*. 1987;138(9):3028-34.
51. Sibley LD, Hunter SW, Brennan PJ, *et al.* Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. *Infect Immun*. 1988;56(5):1232-6.
52. Barnes PF, Chatterjee D, Abrams JS, *et al.* Cytokine production induced by *Mycobacterium tuberculosis* lipoarabinomannan. Relationship to chemical structure. *J Immunol*. 1992;149(2):541-7.
53. Tailleux L, Schwartz O, Herrmann JL, *et al.* DC-SIGN is the major *Mycobacterium tuberculosis* receptor on human dendritic cells. *J Exp Med*. 2003;197(1):121-7.
54. Maeda N, Nigou J, Herrmann JL, *et al.* The cell surface receptor DC-SIGN discriminates between *Mycobacterium* species through selective recognition of the mannose caps on lipoarabinomannan. *J Biol Chem*. 2003;278(8):5513-6.
55. Daffe M, Laneelle MA, Asselineau C, *et al.* Taxonomic value of mycobacterial fatty acids: proposal for a method of analysis. *Ann Microbiol (Paris)*. 1983;134B(2):241-56.
56. Goren MB. Immunoreactive substances of mycobacteria. *Am Rev Respir Dis*. 1982;125(3 Pt 2):50-69.

57. Goren MB, Vatter AE, Fiscus J. Polyanionic agents do not inhibit phagosome-lysosome fusion in cultured macrophages. *J Leukoc Biol.* 1987;41(2):122-9.
58. Minnikin DE, Dobson G, Sesardic D, *et al.* Mycolipenates and mycolipanolates of trehalose from *Mycobacterium tuberculosis*. *J Gen Microbiol.* 1985;131(6):1369-74.
59. Besra GS, Bolton RC, McNeil MR, *et al.* Structural elucidation of a novel family of acyltrehaloses from *Mycobacterium tuberculosis*. *Biochemistry.* 1992;31(40):9832-7.
60. Inderlied CB, Kemper CA, Bermudez LE. The *Mycobacterium avium* complex. *Clin Microbiol Rev.* 1993;6(3):266-310.
61. Falkinham JO, 3rd. Epidemiology of infection by nontuberculous mycobacteria. *Clin Microbiol Rev.* 1996;9(2):177-215.
62. Belisle JT, Brennan PJ. Molecular basis of colony morphology in *Mycobacterium avium*. *Res Microbiol.* 1994;145(3):237-42.
63. Vincent, V., J.K.C., *et al.* 2003. *Mycobacterium* phenotypic and genotypic identification. In: Murray, P.R., Baron, E.J., *et al.* (eds). *Manual of clinical microbiology*, 8<sup>th</sup> edn. Washington, D.C: American Society for Microbiology Press. 560-84.
64. Slutsky AM, Arbeit RD, Barber TW, *et al.* Polyclonal infections due to *Mycobacterium avium* complex in patients with AIDS detected by pulsed-field gel electrophoresis of sequential clinical isolates. *J Clin Microbiol.* 1994;32(7):1773-8.
65. von Reyn CF, Jacobs NJ, Arbeit RD, *et al.* Polyclonal *Mycobacterium avium* infections in patients with AIDS: variations in antimicrobial susceptibilities of different strains of *M. avium* isolated from the same patient. *J Clin Microbiol.* 1995;33(4):1008-10.
66. Abalain-Colloc ML, Guillermin D, Salaun M, *et al.* *Mycobacterium szulgai* isolated from a patient, a tropical fish and aquarium water. *Eur J Clin Microbiol Infect Dis.* 2003;22(12):768-9.
67. Thorel MF, Krichevsky M, Levy-Frebault VV. Numerical taxonomy of mycobactin-dependent mycobacteria, emended description of *Mycobacterium avium*, and description of *Mycobacterium avium* subsp. *avium* subsp. nov.,

- Mycobacterium avium* subsp. *paratuberculosis* subsp. nov., and *Mycobacterium avium* subsp. *silvaticum* subsp. nov. *Int J Syst Bacteriol.* 1990;40(3):254-60.
68. Wolinsky E, Rynearson TK. Mycobacteria in soil and their relation to disease-associated strains. *Am Rev Respir Dis.* 1968;97(6):1032-7.
69. Fry KL, Meissner PS, Falkinham JO, 3rd. Epidemiology of infection by nontuberculous mycobacteria. VI. Identification and use of epidemiologic markers for studies of *Mycobacterium avium*, *M. intracellulare*, and *M. scrofulaceum*. *Am Rev Respir Dis.* 1986;134(1):39-43.
70. du Moulin GC, Stottmeier KD, Pelletier PA, *et al.* Concentration of *Mycobacterium avium* by hospital hot water systems. *Jama.* 1988;260(11):1599-601.
71. Iseman MD. *Mycobacterium avium* complex and the normal host: the other side of the coin. *N Engl J Med.* 1989;321(13):896-8.
72. Lang-Lazdunski L, Offredo C, Le Pimpec-Barthes F, *et al.* Pulmonary resection for *Mycobacterium xenopi* pulmonary infection. *Ann Thorac Surg.* 2001;72(6):1877-82.
73. Guthertz LS, Damsker B, Bottone EJ, *et al.* *Mycobacterium avium* and *Mycobacterium intracellulare* infections in patients with and without AIDS. *J Infect Dis.* 1989;160(6):1037-41.
74. Raszka WV, Jr., Skillman LP, McEvoy PL, *et al.* Isolation of nontuberculous, non-*avium* mycobacteria from patients infected with human immunodeficiency virus. *Clin Infect Dis.* 1995;20(1):73-6.
75. Wolinsky E. Nontuberculous mycobacteria and associated diseases. *Am Rev Respir Dis.* 1979;119(1):107-59.
76. Picardeau M, Prod'Hom G, Raskine L, *et al.* Genotypic characterization of five subspecies of *Mycobacterium kansasii*. *J Clin Microbiol.* 1997;35(1):25-32.
77. Taillard C, Greub G, Weber R, *et al.* Clinical implications of *Mycobacterium kansasii* species heterogeneity: Swiss National Survey. *J Clin Microbiol.* 2003;41(3):1240-4.
78. Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. *Clin Infect Dis.* 1995;20(4):954-63.

79. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: The effects of chemotherapy. *Tubercle*. 1976;57(4):275-99.
80. Boom WH, Wallis RS, Chervenak KA. Human *Mycobacterium tuberculosis*-reactive CD4<sup>+</sup> T-cell clones: heterogeneity in antigen recognition, cytokine production, and cytotoxicity for mononuclear phagocytes. *Infect Immun*. 1991;59(8):2737-43.
81. Flynn JL, Goldstein MM, Triebold KJ, *et al*. Major histocompatibility complex class I-restricted T cells are required for resistance to *Mycobacterium tuberculosis* infection. *Proc Natl Acad Sci U S A*. 1992;89(24):12013-7.
82. Schlesinger LS, Bellinger-Kawahara CG, Payne NR, *et al*. Phagocytosis of *Mycobacterium tuberculosis* is mediated by human monocyte complement receptors and complement component C3. *J Immunol*. 1990;144(7):2771-80.
83. Schlesinger LS. Macrophage phagocytosis of virulent but not attenuated strains of *Mycobacterium tuberculosis* is mediated by mannose receptors in addition to complement receptors. *J Immunol*. 1993;150(7):2920-30.
84. Pethe K, Alonso S, Biet F, *et al*. The heparin-binding haemagglutinin of *M. tuberculosis* is required for extrapulmonary dissemination. *Nature*. 2001;412(6843):190-4.
85. Pasula R, Wisniowski P, Martin WJ, 2nd. Fibronectin facilitates *Mycobacterium tuberculosis* attachment to murine alveolar macrophages. *Infect Immun*. 2002;70(3):1287-92.
86. Horwitz MA. Intracellular parasitism. *Curr Opin Immunol*. 1988;1(1):41-6.
87. McDonough KA, Kress Y, Bloom BR. Pathogenesis of tuberculosis: interaction of *Mycobacterium tuberculosis* with macrophages. *Infect Immun*. 1993;61(7):2763-73.
88. Brown-Elliott BA, Griffith DE, Wallace RJ, Jr. Newly described or emerging human species of nontuberculous mycobacteria. *Infect Dis Clin North Am*. 2002;16(1):187-220.
89. Rigsby MO, Curtis AM. Pulmonary disease from nontuberculous mycobacteria in patients with human immunodeficiency virus. *Chest*. 1994;106(3):913-9.
90. Kesten S, Chaparro C. Mycobacterial infections in lung transplant recipients. *Chest*. 1999;115(3):741-5.



91. Kent, P.T. and Kubica, G.P. 1985. *Public health mycobacteriology a guide for the level III laboratory*. Atlanta, GA: US Department of Health and Human Services, Public Health Service, Centers for Disease Control.
92. Torrens JK, Dawkins P, Conway SP, *et al.* Non-tuberculous mycobacteria in cystic fibrosis. *Thorax*. 1998;53(3):182-5.
93. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. *Clin Microbiol Rev*. 1995;8(4):496-514.
94. Canetti G, Fox W, Khomenko A, *et al.* Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. *Bull World Health Organ*. 1969;41(1):21-43.
95. Atwood HD, Goodman RC, Pope NA, *et al.* The silicone gel breast implant controversy: current status and clinical implications. *J Ark Med Soc*. 1994;90(9):427-34.
96. Zhang Y, Young DB. Molecular mechanisms of isoniazid: a drug at the front line of tuberculosis control. *Trends Microbiol*. 1993;1(3):109-13.
97. Middlebrook G. Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report. *Am Rev Tuberc*. 1954;69(3):471-2.
98. Jin DJ, Gross CA. Mapping and sequencing of mutations in the *Escherichia coli* rpoB gene that lead to rifampicin resistance. *J Mol Biol*. 1988;202(1):45-58.
99. Butler WR, Kilburn JO. Susceptibility of *Mycobacterium tuberculosis* to pyrazinamide and its relationship to pyrazinamidase activity. *Antimicrob Agents Chemother*. 1983;24(4):600-1.
100. Scorpio A, Lindholm-Levy P, Heifets L, *et al.* Characterization of pncA mutations in pyrazinamide-resistant *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 1997;41(3):540-3.
101. Research Committee of the British Thoracic Society, 2001. First randomized trial of treatments for pulmonary disease caused by *M. avium intracellulare*, *M. malmoense*, and *M. xenopi* in HIV negative patients: rifampicin, ethambutol too that of the template mycobacteriophage L5. *Microbiology*, 143, 2701-8.
102. Hoffner SE, Hjelm U, Kallenius G. Susceptibility of *Mycobacterium malmoense* to antibacterial drugs and drug combinations. *Antimicrob Agents Chemother*. 1993;37(6):1285-8.

103. Heginbothom ML. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment. *Int J Tuberc Lung Dis.* 2001;5(6):539-45.
104. Jingu S, Takeshita A, Imaizumi T, *et al.* Exercise training augments cardiopulmonary baroreflex control of forearm vascular resistance in middle-aged subjects. *Jpn Circ J.* 1988;52(2):162-8.
105. Rastogi N, Goh KS, David HL. Enhancement of drug susceptibility of *Mycobacterium avium* by inhibitors of cell envelope synthesis. *Antimicrob Agents Chemother.* 1990;34(5):759-64.
106. Rynearson TK, Shronts JS, Wolinsky E. Rifampin: in vitro effect on atypical mycobacteria. *Am Rev Respir Dis.* 1971;104(2):272-4.
107. Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. *Am Rev Respir Dis.* 1988;137(5):1217-22.
108. Etzkorn ET, Aldarondo S, McAllister CK, *et al.* Medical therapy of *Mycobacterium avium-intracellulare* pulmonary disease. *Am Rev Respir Dis.* 1986;134(3):442-5.
109. Corpe RF. Surgical management of pulmonary disease due to *Mycobacterium avium-intracellulare*. *Rev Infect Dis.* 1981;3(5):1064-7.
110. Wallace RJ, Jr., Brown BA, Griffith DE, *et al.* Initial clarithromycin monotherapy for *Mycobacterium avium-intracellulare* complex lung disease. *Am J Respir Crit Care Med.* 1994;149(5):1335-41.
111. Klein JL, Brown TJ, French GL. Rifampin resistance in *Mycobacterium kansasii* is associated with *rpoB* mutations. *Antimicrob Agents Chemother.* 2001;45(11):3056-8.
112. Wallace RJ, Jr., Dunbar D, Brown BA, *et al.* Rifampin-resistant *Mycobacterium kansasii*. *Clin Infect Dis.* 1994;18(5):736-43.
113. Jacobs MR. Activity of quinolones against mycobacteria. *Drugs.* 1999;58 Suppl 2:19-22.
114. Burman WJ, Stone BL, Brown BA, *et al.* AIDS-related *Mycobacterium kansasii* infection with initial resistance to clarithromycin. *Diagn Microbiol Infect Dis.* 1998;31(2):369-71.

115. Griffith DE. Management of disease due to *Mycobacterium kansasii*. *Clin Chest Med*. 2002;23(3):613-21, vi.
116. Wallace RJ, Jr., Zhang Y, Brown BA, *et al*. Polyclonal *Mycobacterium avium* complex infections in patients with nodular bronchiectasis. *Am J Respir Crit Care Med*. 1998;158(4):1235-44.
117. Colditz GA, Brewer TF, Berkey CS, *et al*. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. *Jama*. 1994;271(9):698-702.
118. Romanus V. First experience with BCG discontinuation in Europe. Experience in Sweden 15 years after stopping general BCG vaccination at birth. *Bull Int Union Tuberc Lung Dis*. 1990;65(2-3):32-5.
119. Butler WR, Thibert L, Kilburn JO. Identification of *Mycobacterium avium* complex strains and some similar species by high-performance liquid chromatography. *J Clin Microbiol*. 1992;30(10):2698-704.
120. Kellogg JA, Bankert DA, Withers GS, *et al*. Application of the Sherlock Mycobacteria Identification System using high-performance liquid chromatography in a clinical laboratory. *J Clin Microbiol*. 2001;39(3):964-70.
121. Salfinger M, Pfyffer GE. The new diagnostic mycobacteriology laboratory. *Eur J Clin Microbiol Infect Dis*. 1994;13(11):961-79.
122. Lipsky BA, Gates J, Tenover FC, *et al*. Factors affecting the clinical value of microscopy for acid-fast bacilli. *Rev Infect Dis*. 1984;6(2):214-22.
123. Morris AJ, Reller LB. Reliability of cord formation in BACTEC media for presumptive identification of mycobacteria. *J Clin Microbiol*. 1993;31(9):2533-4.
124. Vidal R, Martin-Casabona N, Juan A, *et al*. Incidence and significance of acid-fast bacilli in sputum smears at the end of antituberculous treatment. *Chest*. 1996;109(6):1562-5.
125. Roberts GD, Goodman NL, Heifets L, *et al*. Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of *Mycobacterium tuberculosis* from acid-fast smear-positive specimens. *J Clin Microbiol*. 1983;18(3):689-96.

126. Morgan MA, Horstmeier CD, DeYoung DR, *et al.* Comparison of a radiometric method (BACTEC) and conventional culture media for recovery of mycobacteria from smear-negative specimens. *J Clin Microbiol.* 1983;18(2):384-8.
127. Somoskovi A, Magyar P. Comparison of the mycobacteria growth indicator tube with MB redox, Lowenstein-Jensen, and Middlebrook 7H11 media for recovery of mycobacteria in clinical specimens. *J Clin Microbiol.* 1999;37(5):1366-9.
128. Hanna BA, Ebrahimzadeh A, Elliott LB, *et al.* Multicenter evaluation of the BACTEC MGIT 960 system for recovery of mycobacteria. *J Clin Microbiol.* 1999;37(3):748-52.
129. Whyte T, Hanahoe B, Collins T, *et al.* Evaluation of the BACTEC MGIT 960 and MB BAC/T systems for routine detection of *Mycobacterium tuberculosis*. *J Clin Microbiol.* 2000;38(8):3131-2.
130. Woods GL, Fish G, Plaunt M, *et al.* Clinical evaluation of difco ESP culture system II for growth and detection of mycobacteria. *J Clin Microbiol.* 1997;35(1):121-4.
131. Viljanen MK, Olkkonen L, Katila ML. Conventional identification characteristics, mycolate and fatty acid composition, and clinical significance of MAIX AccuProbe-positive isolates of *Mycobacterium avium* complex. *J Clin Microbiol.* 1993;31(5):1376-8.
132. Tortoli E, Nanetti A, Piersimoni C, *et al.* Performance assessment of new Multiplex probe assay for identification of mycobacteria. *J Clin Microbiol.* 2001;39(3):1079-84.
133. Ruiz P, Gutierrez J, Zerolo FJ, *et al.* GenoType *mycobacterium* assay for identification of mycobacterial species isolated from human clinical samples by using liquid medium. *J Clin Microbiol.* 2002;40(8):3076-8.
134. Mijs W, De Vreese K, Devos A, *et al.* Evaluation of a commercial line probe assay for identification of *Mycobacterium* species from liquid and solid culture. *Eur J Clin Microbiol Infect Dis.* 2002;21(11):794-802.
135. Sedlacek L, Rifai M, Feldmann K, *et al.* LightCycler-based differentiation of *Mycobacterium abscessus* and *Mycobacterium chelonae*. *J Clin Microbiol.* 2004;42(7):3284-7.

136. Shrestha NK, Tuohy MJ, Hall GS, *et al.* Detection and differentiation of *Mycobacterium tuberculosis* and nontuberculous mycobacterial isolates by real-time PCR. *J Clin Microbiol.* 2003;41(11):5121-6.
137. Bruijnesteijn Van Coppenraet ES, Lindeboom JA, Prins JM, *et al.* Real-time PCR assay using fine-needle aspirates and tissue biopsy specimens for rapid diagnosis of mycobacterial lymphadenitis in children. *J Clin Microbiol.* 2004;42(6):2644-50.
138. KIDD KK, Ruano G. Optimizing PCR. In: Mcpherson MJ, Hames BD and Taylor GR, editors. PCR 2 (A Practical Approach). 1<sup>st</sup> ed. New York: Oxford University Press; 1995. p. 8-18.
139. Ringuet H, Akoua-Koffi C, Honore S, *et al.* hsp65 sequencing for identification of rapidly growing mycobacteria. *J Clin Microbiol.* 1999;37(3):852-7.
140. Brunello F, Ligozzi M, Cristelli E, *et al.* Identification of 54 mycobacterial species by PCR-restriction fragment length polymorphism analysis of the hsp65 gene. *J Clin Microbiol.* 2001;39(8):2799-806.
141. Takewaki S, Okuzumi K, Manabe I, *et al.* Nucleotide sequence comparison of the mycobacterial dnaJ gene and PCR-restriction fragment length polymorphism analysis for identification of mycobacterial species. *Int J Syst Bacteriol.* 1994;44(1):159-66.
142. Kim BJ, Lee SH, Lyu MA, *et al.* Identification of mycobacterial species by comparative sequence analysis of the RNA polymerase gene (rpoB). *J Clin Microbiol.* 1999;37(6):1714-20.
143. Kapur V, Li LL, Hamrick MR, *et al.* Rapid *Mycobacterium* species assignment and unambiguous identification of mutations associated with antimicrobial resistance in *Mycobacterium tuberculosis* by automated DNA sequencing. *Arch Pathol Lab Med.* 1995;119(2):131-8.
144. Springer B, Stockman L, Teschner K, *et al.* Two-laboratory collaborative study on identification of mycobacteria: molecular versus phenotypic methods. *J Clin Microbiol.* 1996;34(2):296-303.
145. Soini H, Bottger EC, Viljanen MK. Identification of mycobacteria by PCR-based sequence determination of the 32-kilodalton protein gene. *J Clin Microbiol.* 1994;32(12):2944-7.

146. Zolg JW, Philippi-Schulz S. The superoxide dismutase gene, a target for detection and identification of mycobacteria by PCR. *J Clin Microbiol.* 1994;32(11):2801-12.
147. Kasai H, Ezaki T, Harayama S. Differentiation of phylogenetically related slowly growing mycobacteria by their *gyrB* sequences. *J Clin Microbiol.* 2000;38(1):301-8.
148. Roth A, Reischl U, Schonfeld N, *et al.* *Mycobacterium heckeshornense* sp. nov., A new pathogenic slowly growing Mycobacterium sp. Causing cavitary lung disease in an immunocompetent patient. *J Clin Microbiol.* 2000;38(11):4102-7.
149. [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)(GenBank/EMNL) and [www.ridom.de/mycobacteria/](http://www.ridom.de/mycobacteria/))
150. Wayne LG, Good RC, Bottger EC, *et al.* Semantide- and chemotaxonomy-based analyses of some problematic phenotypic clusters of slowly growing mycobacteria, a cooperative study of the International Working Group on Mycobacterial Taxonomy. *Int J Syst Bacteriol.* 1996;46(1):280-97.
151. Amplicor, Roche Diagnostic Systems, Branchburg, NJ; Probetec, BD Biosciences, Sparks, MD.
152. Vlasplolder F, Singer P, Roggeveen C. Diagnostic value of an amplification method (Gen-Probe) compared with that of culture for diagnosis of tuberculosis. *J Clin Microbiol.* 1995;33(10):2699-703.
153. Pfyffer GE, Kissling P, Jahn EM, *et al.* Diagnostic performance of amplified *Mycobacterium tuberculosis* direct test with cerebrospinal fluid, other nonrespiratory, and respiratory specimens. *J Clin Microbiol.* 1996;34(4):834-41.
154. D'Amato RF, Wallman AA, Hochstein LH, *et al.* Rapid diagnosis of pulmonary tuberculosis by using Roche AMPLICOR *Mycobacterium tuberculosis* PCR test. *J Clin Microbiol.* 1995;33(7):1832-4.
155. Piersimoni C, Callegaro A, Nista D, *et al.* Comparative evaluation of two commercial amplification assays for direct detection of *Mycobacterium tuberculosis* complex in respiratory specimens. *J Clin Microbiol.* 1997;35(1):193-6.
156. Alcalá L, Ruiz-Serrano MJ, Hernangomez S, *et al.* Evaluation of the upgraded amplified *Mycobacterium tuberculosis* direct test (gen-probe) for direct detection

of *Mycobacterium tuberculosis* in respiratory and non-respiratory specimens. *Diagn Microbiol Infect Dis*. 2001;41(1-2):51-6.

157. Tjhie JH, van Belle AF, Dessens-Kroon M, *et al*. Misidentification and diagnostic delay Caused by a false-positive amplified *Mycobacterium tuberculosis* direct test in an immunocompetent patient with a *Mycobacterium celatum* infection. *J Clin Microbiol*. 2001;39(6):2311-2.
158. Sansila A, Hongmanee P, Chuchottaworn C, *et al*. Differentiation between *Mycobacterium tuberculosis* and *Mycobacterium avium* by amplification of the 16S-23S ribosomal DNA spacer. *J Clin Microbiol* 1998;36(9): 2399-403.
159. Van Soolingen D, Bauer J, Ritacco V, *et al*. IS1245 Restriction Fragment Length Polymorphism Typing of *Mycobacterium avium* Isolates: Proposal for Standardization. *J. Clin. Microbiol.*1998; 36(10): 3051 - 3054.
160. Park H, Kim C, Park KH, *et al*. Development and evaluation of triplex PCR for direct detection of mycobacteria in respiratory specimens. *J Appl Microbiol*. 2006;100(1):161-7.
161. LoBue P. Extensively drug-resistant tuberculosis. *Curr Opin Infect Dis*. 2009;22(2):167-73.
162. <http://www.cdc.gov/ncidod/EID/vol8no11/02-0318.htm>
163. Wu X, Zhang J, Liang J, *et al*. Comparison of three methods for rapid identification of mycobacterial clinical isolates to the species level. *J Clin Microbiol*. 2007;45(6):1898-903.
164. Foongladda S, Pholwat S, Eampokalap B, *et al*. Multi-probe real-time PCR identification of common *Mycobacterium* species in blood culture broth. *J Mol Diagn*. 2009;11(1):42-8.
165. Hughes MS, Skuce RA, Beck LA, *et al*. Identification of mycobacteria from animals by restriction enzyme analysis and direct DNA cycle sequencing of polymerase chain reaction-amplified 16S rRNA gene sequences. *J Clin Microbiol*. 1993;31(12):3216-22.

166. Rogall T, Flohr T, Bottger EC. Differentiation of *Mycobacterium* species by direct sequencing of amplified DNA. *J Gen Microbiol.* 1990;136(9):1915-2



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่  
Copyright© by Chiang Mai University  
All rights reserved